8534 Hyperfractionated radiotherapy with concurrent docetaxel in locally-advanced head and neck cancer

Karasawa, Kumiko; Izawa, Hiromi; Hirowatari, Hisako; Ito, Kei; Furuya, T.; Ozawa, Shogo; Matsumoto, Fumihiko; S, Itó; Oba, Shinichi; Ikeda, Kenichirou

doi:10.1016/s1359-6349(09)71625-8

Cited by 5 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The schedule of docetaxel consisted of mainly 6 cycles in previous studies [14, 24, 26, 27]. In the matched cohort of the present study, all patients in the docetaxel group received 3 cycles of chemotherapy, 54 (24.1%) received 4 or more cycles; 167 (74.6%) patients in the docetaxel group suffered grade 3 mucositis, which was much higher than those in previous studies (range from 27.9% to 61.4%) [14, 24, 28]. The main reason may be related to the use of IMRT which increases the radiation dose to the target area and thus leading to an increased risk of severe mucositis.…”

Section: Discussionmentioning

confidence: 44%

“…Previous studies revealed that mucositis was the most common restrictive factor in CCRT with docetaxel [27]. Several phase I/II studies reported that a weekly dose of docetaxel between 10 and 20 mg/m 2 demonstrated acceptable toxicity and therapeutic activity [26, 28]. Calais et al [27] reported a phase II trial of CCRT with weekly docetaxel at 20 mg/m 2 for patients with stage III/IV oropharyngeal carcinoma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis

Liao¹,

Zhang

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

Background Promising efficacy and manageable toxicity of docetaxel-based concurrent chemoradiotherapy (CCRT) were reported in head and neck cancer. In addition, the effect of CCRT in combination with cisplatin and/or 5-fluorouracil on both locoregionally advanced and metastatic/recurrent nasopharyngeal carcinoma (NPC) was verified. However, CCRT with docetaxel for locoregionally advanced NPC are not well studied. This study aimed to compare effectiveness and toxicities of CCRT with weekly docetaxel versus tri-weekly cisplatin for locoregionally advanced NPC. Methods Clinical data of patients with locoregionally advanced NPC newly diagnosed between January 2010 and December 2014 receiving CCRT with either weekly docetaxel (15 mg/m 2 ) or tri-weekly cisplatin (80–100 mg/m 2 ) were reviewed. Propensity score matching at a 1:1 ratio was performed to balance baseline characteristics. Adverse events and survival were compared between the two groups. Results A total of 962 patients were included as the whole cohort, and 448 patients were matched and were regarded as the matched cohort. The median follow-up duration was 48 months for the whole cohort. The 3-year nodal recurrence-free survival rate was significantly increased for patients treated with docetaxel in both the whole (hazard ratio [HR] = 0.37, 95% confidence interval [CI] 0.19–0.72, P = 0.030) and matched cohorts (HR = 0.33, 95% CI 0.14–0.79, P = 0.023). However, no significant differences were observed in overall survival, local recurrence-free survival, and distant metastasis-free survival between the two groups in both cohorts. Significantly higher rates of grade 3 radiodermatitis (6.7% vs. 1.8%, P = 0.001), mucositis (74.5% vs. 37.9%, P < 0.001), and leucopenia (2.2% vs. 11.6%, P < 0.001) were observed in the docetaxel group, but any grade of renal injury (1.8% vs. 15.1%, P < 0.001), vomiting (18.8% vs. 88.3%, P < 0.001), and ALT elevation (19.2% vs. 31.3%, P = 0.027) were more common in the cisplatin group. Conclusions CCRT with weekly low-dose docetaxel is an effective and tolerable therapeutic regimen for locally advanced NPC. It provides a survival benefit mainly by improving the control of regional lymph node metastases, especially for patients with low pretreatment EBV DNA levels. Electronic supplementary material The online version of this article (10.1186/s40880-019-0380-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 44%

Section: Discussionmentioning

confidence: 99%

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis

Liao¹,

Zhang

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

show abstract

“…This has been done recently with a paclitaxel, a related drug [ 4 ]. Furthermore, clinical trials based on combinatorial treatment of radiotherapy and DTX are already underway to improve the therapeutic outcome while minimizing side effects through reducing individual doses [ 46 , 47 , 48 , 49 , 50 , 51 , 52 ]. The addition of GNPs to these protocols is possible considering their biocompatibility.…”

Section: Discussionmentioning

confidence: 99%

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) have shown promise in both radiotherapy and chemotherapy. NPs are mainly transported along cellular microtubules (MTs). Docetaxel (DTX) is a commonly used chemotherapeutic drug that can manipulate the cellular MT network to maximize its clinical benefit. However, the effect of DTX on NP behaviour has not yet been fully elucidated. We used gold NPs of diameters 15 and 50 nm at a concentration of 0.2 nM to investigate the size dependence of NP behaviour. Meanwhile, DTX concentrations of 0, 10 and 50 nM were used to uphold clinical relevance. Our study reveals that a concentration of 50 nM DTX increased NP uptake by ~50% and their retention by ~90% compared to cells treated with 0 and 10 nM DTX. Smaller NPs had a 20-fold higher uptake in cells treated with 50 nM DTX vs. 0 and 10 nM DTX. With the treatment of 50 nm DTX, the cells became more spherical in shape, and NPs were redistributed closer to the nucleus. A significant increase in NP uptake and retention along with their intracellular distribution closer to the nucleus with 50 nM DTX could be exploited to target a higher dose to the most important target, the nucleus in both radiotherapy and chemotherapy.

show abstract

“…Grade 3-4 toxicities in the studies of concurrent chemoradiotherapy with docetaxel and platinum in the literature mucositis 14-81%, dysphagia 13-50%, nausea and vomiting 6%, weight loss 12%, neutropenia 1-14% and anemia were reported and thrombocytopenia were not observed (Karasawa et al, 2002;Schwartz et al, 2005;Matsumoto et al, 2006;Chitapanarux et al, 2011). In our study, grade 3-4 toxicities rates were similar in the literature; mucositis 36.4%, nausea and vomiting 12.1%, weight loss 1.5%, neutropenia 4.5% and grade 3-4 anemia and thrombocytopenia were not observed.…”

Section: Discussionmentioning

confidence: 99%

“…In the studies where docetaxel combined with platinum at concomitant chemoradiotherapy, ORR varied from 74-100% (Karasawa et al, 2002;Schwartz et al, 2005;Chitapanarux et al, 2011). OS for two years were reported as 65% (25-26), DFS for 2 years were 63% (Chitapanarux et al, 2011) and PFS for 2 years were 61% .…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

Baykara

Büyükberber²,

Öztürk³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

8534 Hyperfractionated radiotherapy with concurrent docetaxel in locally-advanced head and neck cancer

Cited by 5 publications

References 0 publications

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis

Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score‐matched analysis

Modulation of the Microtubule Network for Optimization of Nanoparticle Dynamics for the Advancement of Cancer Nanomedicine

Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers

Contact Info

Product

Resources

About